mutation class

Gene Expression

synonyms

HER2

HER2+

HER2(+)

HER2+ve

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

267 sites for NCT04784715

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +2 more drugs

targeted therapy

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

144 sites for NCT05113251

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

fam-trastuzumab deruxtecan, +3 more drugs

chemotherapy, +1 more type

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial

577 sites for NCT04457596

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

357 sites for NCT04622319

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy

261 sites for NCT04873362

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

immunotherapy, +1 more type

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

534 sites for NCT04266249

ERBB2 Amplification, +1 more biomarker

Invasive Breast Carcinoma

ado-trastuzumab emtansine, +6 more drugs

chemotherapy, +2 more types

pembrolizumab + trastuzumab + fluoropyrimidine + platinum chemotherapy

ERBB2 Amplification, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

Locally advanced, +2 more states

First line

fluoropyrimidine, +3 more drugs

chemotherapy, +2 more types

fam-trastuzumab deruxtecan

ERBB2 Amplification, +1 more biomarker

Adenocarcinoma of the Gastroesophageal Junction, +1 more condition

Locally advanced, +1 more state

Subsequent line

fam-trastuzumab deruxtecan

targeted therapy

margetuximab + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic

Subsequent line

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Early stage, +1 more state

Neoadjuvant

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + chemotherapy

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Early stage

Adjuvant

chemotherapy, +1 more drug

chemotherapy, +1 more type

pertuzumab/trastuzumab/hyaluronidase + docetaxel

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

Metastatic

First line

docetaxel, +1 more drug

chemotherapy, +1 more type